NCT05926869|CompletedPhase 2
Loading search results
Sponsor study identifier
interventional
100
1 country
1
Study Start
August 1, 2022
Actual (reported)Primary Completion
December 1, 2022
Actual (reported)Study Completion
February 1, 2023
Actual (reported)Acne vulgaris (AV) is a disease of the pilosebaceous unit that causes noninflammatory lesions (open and closed comedones), inflammatory lesions (papules, pustules, and nodules), and varying degrees of scarring. The key pathogenic processes includes alteration of follicular keratinization that leads to comedones; increased and altered sebum production under androgen control; follicular colonization by Propionibacterium acnes; . The role of topical antibiotics in treating acne is well established. Clindamycin is a topical antibiotic which has been widely used in treatment of acne for many decades. The extensive use of antibiotics in acne has lead to the development of resistance to antimicrobial therapy. Dapsone is known to have antibacterial as well as anti-inflammatory action which may help in reduction of acne.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
February 1, 2023
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
August 1, 2022
Actual (reported)December 1, 2022
Actual (reported)February 1, 2023
Actual (reported)March 22, 2023
Actual (reported)July 3, 2023
Actual (reported)Comparison of the Efficacy of Clindamycin Phosphate 1% Gel Versus Once-daily Dapsone 5% Gel in the Treatment of Moderate Acne Vulgaris
Efficacy will be assessed using Global Acne Grading Sore ( GAGS ). For GAGS (Score 1-18 = mild, score 19-30 = moderate, score 31-38 = severe). Mean difference of GAGs score before and after the treatment will be calculated.
It will be assessed upto 03 months
Clindamycin is a topical antibiotic which has been widely used in treatment of acne for many decades. Topical Dapsone 5% gel contains sulfone and has an advanced solvent micro particulate delivery system that enables penetration of stratum corneum . It is a new topical drug used in the treatment of Moderate Acne Vulgaris. It has antibacterial as well as anti inflammatory effects
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
These entries preserve how the registry describes the intervention. Their treatment roles are shown separately from molecular identities.
Grouped treatment entry
Clindamycin and Dapsone gel for 03 months
The registry names several treatments. This does not confirm that participants received them together or that they form a single product.
View registry recordJPMC
Karachi, Sindh, Pakistan
khadija Asadullah, FCPS
Jpmc
Faiza Inam, FCPS
Jpmc
Nazia Jabeen, FCPS
JPMC
100 participants (actual enrollment reported by the registry).
First Submitted
March 22, 2023
First Posted
July 3, 2023
Study Start
August 1, 2022
Actual (reported)Contact the study team to confirm eligibility.
Primary Completion
December 1, 2022
Actual (reported)Study Completion
February 1, 2023
Actual (reported)Last Updated
July 3, 2023
Record last verified: 2023-06
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: